This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Applied Genetic Technologies Dividende

Dividende contrôle des critères 0/6

Informations clés

n/a

Rendement du dividende

n/a

Ratio de distribution

Rendement moyen de l'industrie	1.9%
Prochaine date de paiement du dividende	n/a
Date ex-dividende	n/a
Dividende par action	n/a
Résultat par action	-US$2.19
Prévision de rendement du dividende	n/a

Mises à jour récentes des dividendes

Pas de mise à jour

Recent updates

AGTC receives positive feedback from FDA for manufacturing facility

Jul 26

Applied Genetic Technologies proposes stock offering to fund clinical trials

Jul 12

Applied Genetic Tech: A Speculative Biotech With Potential To Turn Corner In 2022

Jan 12

An Assessment Of Applied Genetic Technologies Corporation

Dec 14

Applied Genetic Technologies: Weak Early Clinical Ocular Results Highlight Increased Risk

Jul 15

Is Applied Genetic Technologies (NASDAQ:AGTC) A Risky Investment?

May 21

Applied Genetic trades lower after announcing the departure of chief scientific officer

Apr 26

What Is The Ownership Structure Like For Applied Genetic Technologies Corporation (NASDAQ:AGTC)?

Feb 05

Is Applied Genetic Technologies (NASDAQ:AGTC) Using Debt In A Risky Way?

Jan 06

What Type Of Returns Would Applied Genetic Technologies'(NASDAQ:AGTC) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Dec 11

Interim data on gene therapy for vision loss disorder fails to lift Applied Genetic

Nov 11

Stabilité et croissance des paiements

Récupération des données sur les dividendes

Dividende stable: Insufficient data to determine if AGTC's dividends per share have been stable in the past.

Dividende croissant: Insufficient data to determine if AGTC's dividend payments have been increasing.

Rendement des dividendes par rapport au marché

Applied Genetic Technologies Rendement des dividendes par rapport au marché

Comment le rendement du dividende de AGTC se compare-t-il à celui du marché ?
Segment	Rendement du dividende
Entreprise (AGTC)	n/a
25% du marché (US)	1.4%
25% du marché (US)	4.4%
Moyenne du secteur (Biotechs)	1.9%
Analyste prévisionnel (AGTC) (jusqu'à 3 ans)	n/a

Dividende notable: Unable to evaluate AGTC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Dividende élevé: Unable to evaluate AGTC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Bénéfice distribué aux actionnaires

Couverture des revenus: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Paiement en espèces aux actionnaires

Couverture des flux de trésorerie: Unable to calculate sustainability of dividends as AGTC has not reported any payouts.

This company has been acquired

Applied Genetic Technologies Dividende

Dividende contrôle des critères 0/6

Informations clés

Mises à jour récentes des dividendes

Recent updates

Applied Genetic Technologies Corporation(NasdaqGM:AGTC) dropped from NASDAQ Composite Index

Syncona Limited (LSE:SYNC), a fund managed by Syncona Investment Management Limited completed the acquisition of Applied Genetic Technologies Corporation (NasdaqGM:AGTC).

Applied Genetic Technologies Corporation announced delayed 10-Q filing

Insufficient new directors

Syncona Limited (LSE:SYNC), a fund managed by Syncona Investment Management Limited, entered into a definitive agreement to acquire Applied Genetic Technologies Corporation (NasdaqGM:AGTC) for $23.3 million.

Price target decreased to US$8.00

AGTC receives positive feedback from FDA for manufacturing facility

Applied Genetic Technologies Corporation has completed a Follow-on Equity Offering.

Applied Genetic Technologies Corporation has completed a Follow-on Equity Offering.

Applied Genetic Technologies proposes stock offering to fund clinical trials

Applied Genetic Technologies Receives Non-Compliance Notice from Nasdaq

Price target decreased to US$10.57

Applied Genetic Technologies Corporation Announces Executive Appointments

Price target decreased to US$14.13

AGTC Announces Positive Three-Month Interim Results from Skyline Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa

Applied Genetic Technologies Corporation Presents Positive 18-Month Data from Ongoing Phase 1/2 Clinical Study of AGTC-501 At the Association for Research in Vision and Ophthalmology 2022 Annual Meeting

Insufficient new directors

Ivana Magovcevic-Liebisch Resigns from Board of Directors and Each Committee of Which She Was A Member of Applied Genetic Technologies Corporation, Effective March 9, 2022

Applied Genetic Technologies Reports Updated Interim Three-Month Pediatric Results and Additional Adult Safety Results Out to as Long as 24 Months from Its Ongoing Phase 1/2 Dose Escalation Study of AGTC-401

Applied Genetic Technologies Corporation to Report Q2, 2022 Results on Feb 14, 2022

AGTC Exceeds Enrollment Target in SKYLINE Trial of AGTC-501 for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

Applied Genetic Tech: A Speculative Biotech With Potential To Turn Corner In 2022

An Assessment Of Applied Genetic Technologies Corporation

Insufficient new directors

Insufficient new directors

Applied Genetic Technologies Corporation Announces Ongoing Clinical Trials in achromatopsia and X-Linked Retinitis Pigmentosa at the Fourteenth International Symposium on Retinal Degeneration

Applied Genetic Technologies: Weak Early Clinical Ocular Results Highlight Increased Risk

Applied Genetic Technologies Corporation(NasdaqGM:AGTC) dropped from Russell 3000E Index

Applied Genetic Technologies Corporation Reports 12-Month Data from Its Ongoing Phase 1/2 Achromatopsia Clinical Trials Showing Biologic Activity in Patients with Mutations in the ACHM B3 Gene

Is Applied Genetic Technologies (NASDAQ:AGTC) A Risky Investment?

Otonomy, Inc. and Applied Genetic Technologies Corporation Present Preclinical Proof-Of-Concept Results for Oto-825 Gene Therapy At ASGCT Annual Meeting

Applied Genetic Technologies Corporation Advances for Manufacturing its XLRP Gene Therapy Candidate in Two Abstracts at ASGCT

Applied Genetic Technologies Corporation Reports Additional Positive Data from the Ongoing X-Linked Retinitis Pigmentosa Phase 1/2 Clinical Trial

Agtc Clinical Investigators Provide Encore Presentation of Data from the Company’s Ongoing XLRP and Achromatopsia Phase 1/2 Trials

Applied Genetic trades lower after announcing the departure of chief scientific officer

Earnings beat expectations

What Is The Ownership Structure Like For Applied Genetic Technologies Corporation (NASDAQ:AGTC)?

Applied Genetic Technologies Corporation to Report Q2, 2021 Results on Feb 11, 2021

Price target lowered to US$11.44

Applied Genetic Technologies Corporation has completed a Follow-on Equity Offering in the amount of $74.5 million.

New 90-day low: US$3.95

Applied Genetic Technologies Corporation Announces First Reported Improvements in Visual Sensitivity for Achromatopsia Patients from Its Ongoing Clinical Trials

Is Applied Genetic Technologies (NASDAQ:AGTC) Using Debt In A Risky Way?

What Type Of Returns Would Applied Genetic Technologies'(NASDAQ:AGTC) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

New 90-day low: US$4.33

Earnings beat expectations

Applied Genetic Technologies Corporation Reports Additional Positive Data from its Phase 1/2 Clinical Trial in Patients with X-Linked Retinitis Pigmentosa

Interim data on gene therapy for vision loss disorder fails to lift Applied Genetic

Applied Genetic Technologies Corporation Plans to Release 12-Month Data for Groups 1 Through 4 Evaluating Durability of Effect and Continued Safety and Interim Data of Groups 5 and 6 Evaluating Safety and Efficacy at Higher Doses for its Phase 1/2 Clinical Trial

Applied Genetic Technologies Corporation, Annual General Meeting, Dec 16, 2020

Applied Genetic Technologies Corporation Joins the My Retina Tracker® Program as A New Scientific Collaborator

Full year earnings released - US$2.17 loss per share

New 90-day low - US$4.55

Full year earnings released - US$2.17 loss per share

Applied Genetic Technologies Corporation to Report Q4, 2020 Results on Sep 09, 2020

Stabilité et croissance des paiements

Rendement des dividendes par rapport au marché

Bénéfice distribué aux actionnaires

Paiement en espèces aux actionnaires

Découvrir des entreprises qui versent des dividendes élevés